BioArctic AB (publ) (BRCTF)
POSITIVEPrice
$302.40
Market Cap
$26.83B
Fundamental
72
Technical
75
Composite
73
AI Analysis
Generated on demand using your Gemini API key
Gemini API key not configured
Add your Gemini API key in Settings to unlock AI analysis.
Overview
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is in phase 3 clinical trials for presymptomatic treatment; Exidavnemab, which is in phase 2 clinical trials; Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Balance Sheet & Liquidity
Revenue
$2.00B
Net Income
$1.02B
Free Cash Flow
$1.26B
Total Equity
$1.84B
Total Liabilities
$41M
Current Ratio
6.54
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Fair Value Estimation
Fairly ValuedFair Value
$303.43
Current Price
$302.40
Margin of Safety
+0.3%
Fair Value Range
$197.23 - $409.63
Estimation Methods
Valuation Metrics
P/E Ratio
126.53
ROE
10.3%
P/B Ratio
12.21
P/FCF
17.86
Gross Margin
94.1%
ROIC
22.1%
Value Creation (Economic Moat)
ROIC
22.1%
WACC
8.0%
ROIC − WACC
+14.1 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (14)
- Price CAGR 30.27%
- ROIC 22.1%
- Gross Margin 94.1%
- P/FCF 17.86
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- ROE 10.4%
- Revenue Growth 5Y 100.1%
- Analyst Consensus 73% Buy
- Earnings Surprise avg 453.0%
- Earnings Quality (OCF/NI) 1.23
- Net Margin Trend 51.1% vs -68.8%
Failed (3)
- P/B Ratio 12.21
- DCF valuation (Fairly valued)
- Piotroski F-Score 2/9
Unavailable (10)
- EPS data insufficient
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Price Chart
Technical Indicators
RSI (14)
44.42
SMA 50
$321.79
SMA 200
$308.79
MACD
-3.94
Volatility
4.0%
Momentum (12m)
49.9%
RSI 44.4, SMA trend bullish, momentum 49.9%.
Piotroski F-Score
Serious financial concerns
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Gunilla Osswald Ph.D. | President & CEO | 64 |
| Dr. Pär Gellerfors | Co-Founder & Senior VP of Business Strategy | 78 |
| Prof. Lars Lannfelt | Co-Founder, Senior VP of Medical science & Director | 76 |
| Mr. Anders Martin-Lof M.B.A., M.Sc. | Secretary of the Board & CFO | 54 |
| Mr. Per-Ola Freskgard | Chief Scientific Officer | - |
| Mr. Oskar Bosson | VP and Head of IR & Communication | 49 |
| Ms. Emilie Ankarcrona Smith | General Counsel and Head of Legal & IP | 44 |
| Mr. Harald Borgeke | Head of Public Affairs | - |
| Ms. Frida Lekander | Head of Marketing | - |
| Ms. Rebecca Kastell | VP & Head of HR | 47 |
Latest News
Recent headlines for BRCTF, sourced from Markets Gazette.